Skip to main content
. 2024 Aug 1;9(32):34358–34369. doi: 10.1021/acsomega.4c01361

Figure 10.

Figure 10

Structure–activity relationship of compounds 4–15 as dual EGFR/VEGFR-2 inhibitors.